Medicines and Healthcare products Regulatory Agency (MHRA), 2025
Therapie 2020;75:641-7.ArticlePubMed 12
Thus, exenatide treated patients maintained their cognitive benefit 12-months following drug cessation, however, it should be noted that cognitive scores also remained unchanged for controls between 12 and 24 months
Glucagon-like peptide-1 ameliorates cardiac lipotoxicity in diabetic cardiomyopathy via the PPAR pathway
If approved for the treatment of obesity, orforglipron could provide a convenient alternative for the millions of individuals living with obesity around the globe to continue their long-term health journey, said Kenneth Custer, executive vice president at Eli Lilly and president of Lilly Cardiometabolic Health, in a statement from the company
Glucagon-like peptide-1 enhances cardiac L-type Ca 2+ currents via activation of the cAMP-dependent protein kinase A pathway